Cargando…

Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF

OBJECTIVE: To describe and identify factors associated with articular manifestations occurring in patients treated with anti-tumour necrosis factor (TNF) for inflammatory bowel diseases (IBDs). METHODS: Retrospective monocentric study, including all patients who received an anti-TNF for an IBD in ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Cachen, Laurie, Nocturne, Gaetane, Collins, Michael, Meyer, Antoine, Gleizes, Aude, Hacein-Bey-Abina, Salima, Carbonnel, Franck, Mariette, Xavier, Seror, Raphaele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804691/
https://www.ncbi.nlm.nih.gov/pubmed/35091460
http://dx.doi.org/10.1136/rmdopen-2021-001697
_version_ 1784643135884754944
author Cachen, Laurie
Nocturne, Gaetane
Collins, Michael
Meyer, Antoine
Gleizes, Aude
Hacein-Bey-Abina, Salima
Carbonnel, Franck
Mariette, Xavier
Seror, Raphaele
author_facet Cachen, Laurie
Nocturne, Gaetane
Collins, Michael
Meyer, Antoine
Gleizes, Aude
Hacein-Bey-Abina, Salima
Carbonnel, Franck
Mariette, Xavier
Seror, Raphaele
author_sort Cachen, Laurie
collection PubMed
description OBJECTIVE: To describe and identify factors associated with articular manifestations occurring in patients treated with anti-tumour necrosis factor (TNF) for inflammatory bowel diseases (IBDs). METHODS: Retrospective monocentric study, including all patients who received an anti-TNF for an IBD in our hospital. All incident articular manifestations occurring during treatment were analysed. Characteristics of patients with paradoxical articular manifestations were compared with that of patients without inflammatory articular manifestations. RESULTS: Between February 2013 and May 2017, we identified 442 patients (36.2±15 years, 50.5% men) who had ever received an anti-TNF for an IBD: Crohn’s disease (n=277), ulcerative colitis (n=154) and undetermined colitis (n=11). 115 (26%) patients developed new articular manifestations after a mean of 20 (±22) months of treatment. Among them, 59 (13.3%) had inflammatory manifestations: paradoxical in 39%, concomitant of an IBD flare in 27%, linked to an immunisation against anti-TNF in 27% and 7% to another diagnosis. Among paradoxical articular manifestations, 19 (83%) were new articular symptoms, including 8 (35%) de novo spondyloarthritis. There were no predictive factors of paradoxical articular manifestation. Paradoxical manifestations spontaneously resolved in 16 (70%) patients despite continuation of anti-TNF. CONCLUSION: Inflammatory articular manifestations occurred in about 13% of patients treated with anti-TNF for IBD. More than a quarter were linked to an immunisation against anti-TNF, which has to be searched in this situation. About 40% were paradoxical. In most of cases, they were transitory and did not require anti-TNFs discontinuation.
format Online
Article
Text
id pubmed-8804691
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-88046912022-02-07 Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF Cachen, Laurie Nocturne, Gaetane Collins, Michael Meyer, Antoine Gleizes, Aude Hacein-Bey-Abina, Salima Carbonnel, Franck Mariette, Xavier Seror, Raphaele RMD Open Treatments OBJECTIVE: To describe and identify factors associated with articular manifestations occurring in patients treated with anti-tumour necrosis factor (TNF) for inflammatory bowel diseases (IBDs). METHODS: Retrospective monocentric study, including all patients who received an anti-TNF for an IBD in our hospital. All incident articular manifestations occurring during treatment were analysed. Characteristics of patients with paradoxical articular manifestations were compared with that of patients without inflammatory articular manifestations. RESULTS: Between February 2013 and May 2017, we identified 442 patients (36.2±15 years, 50.5% men) who had ever received an anti-TNF for an IBD: Crohn’s disease (n=277), ulcerative colitis (n=154) and undetermined colitis (n=11). 115 (26%) patients developed new articular manifestations after a mean of 20 (±22) months of treatment. Among them, 59 (13.3%) had inflammatory manifestations: paradoxical in 39%, concomitant of an IBD flare in 27%, linked to an immunisation against anti-TNF in 27% and 7% to another diagnosis. Among paradoxical articular manifestations, 19 (83%) were new articular symptoms, including 8 (35%) de novo spondyloarthritis. There were no predictive factors of paradoxical articular manifestation. Paradoxical manifestations spontaneously resolved in 16 (70%) patients despite continuation of anti-TNF. CONCLUSION: Inflammatory articular manifestations occurred in about 13% of patients treated with anti-TNF for IBD. More than a quarter were linked to an immunisation against anti-TNF, which has to be searched in this situation. About 40% were paradoxical. In most of cases, they were transitory and did not require anti-TNFs discontinuation. BMJ Publishing Group 2022-01-28 /pmc/articles/PMC8804691/ /pubmed/35091460 http://dx.doi.org/10.1136/rmdopen-2021-001697 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Treatments
Cachen, Laurie
Nocturne, Gaetane
Collins, Michael
Meyer, Antoine
Gleizes, Aude
Hacein-Bey-Abina, Salima
Carbonnel, Franck
Mariette, Xavier
Seror, Raphaele
Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
title Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
title_full Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
title_fullStr Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
title_full_unstemmed Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
title_short Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
title_sort articular manifestations in patients with inflammatory bowel diseases treated with anti-tnf
topic Treatments
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804691/
https://www.ncbi.nlm.nih.gov/pubmed/35091460
http://dx.doi.org/10.1136/rmdopen-2021-001697
work_keys_str_mv AT cachenlaurie articularmanifestationsinpatientswithinflammatoryboweldiseasestreatedwithantitnf
AT nocturnegaetane articularmanifestationsinpatientswithinflammatoryboweldiseasestreatedwithantitnf
AT collinsmichael articularmanifestationsinpatientswithinflammatoryboweldiseasestreatedwithantitnf
AT meyerantoine articularmanifestationsinpatientswithinflammatoryboweldiseasestreatedwithantitnf
AT gleizesaude articularmanifestationsinpatientswithinflammatoryboweldiseasestreatedwithantitnf
AT haceinbeyabinasalima articularmanifestationsinpatientswithinflammatoryboweldiseasestreatedwithantitnf
AT carbonnelfranck articularmanifestationsinpatientswithinflammatoryboweldiseasestreatedwithantitnf
AT mariettexavier articularmanifestationsinpatientswithinflammatoryboweldiseasestreatedwithantitnf
AT serorraphaele articularmanifestationsinpatientswithinflammatoryboweldiseasestreatedwithantitnf